Recifercept for Achondroplasia - the new designation
Recifercept is the name Pfizer has selected for the orphan drug for achondroplasia. Pfizer acquired Therachon in May 2019 (Pfizer press release here) and with that, TA-46, the molecule being developed as a potential treatment for achondroplasia. The acquisition process was concluded in September 2019, and now the company is has listed the new name at their Pipeline page. Both "Therachon" and "TA-46" are no longer in use.
Pfizer has an increased potential to deliver an effective trial, based on the experience, structure, logistical and financial strengths of the company. New information regarding the Phase 2 clinical trial is expected to be disclosed soon.
Nevertheless, is still time to remember the excellent work that was achieved by Therachon team with the development of the soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy, that as the potential to reduce the complications in achondroplasia, with a high safety profile (based on existent pre-clinical information).